In its third letter of the year, the FDA's Office of Prescription Drug Promotion (OPDP) came down on Celator Pharmaceuticals Inc. for promoting a promising but yet-to-be-approved cancer drug in an exhibit at the American Society for Clinical Oncology's (ASCO) annual meeting in June.